VSee Health (VSEE) director granted stock under 2024 plan in Form 4 filing

Rhea-AI Filing Summary

VSee Health, Inc. director David L. Wickersham reported multiple stock awards of common shares on September 19, 2025. Each transaction is coded as an acquisition and represents shares issued under the company's 2024 Incentive Plan in line with its non-employee director compensation policy.

The footnotes explain that these grants compensate his board service for quarters ended September 30, 2025, June 30, 2025, March 31, 2025, December 31, 2024, and September 30, 2024, with the number of shares for each period based on the closing stock price on the relevant date. One award shows 21,870 shares at $0.69 per share, and after that transaction he directly beneficially owned 282,397 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WICKERSHAM DAVID L.

(Last) (First) (Middle)

C/O VSEE HEALTH, INC.

980 N FEDERAL HWY #304

(Street)

BOCA RATON FL 33432

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VSEE HEALTH, INC. [ VSEE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	09/19/2025		A		21,870	A	$0.69(1)	282,397	D
Common Stock, par value $0.0001 per share	09/19/2025		A		12,931	A	$1.16(2)	260,527	D
Common Stock, par value $0.0001 per share	09/19/2025		A		12,500	A	$1.2(3)	247,596	D
Common Stock, par value $0.0001 per share	09/19/2025		A		11,029	A	$1.36(4)	235,096	D
Common Stock, par value $0.0001 per share	09/19/2025		A		10,067	A	$1.49(5)	224,067	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended September 30, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on September 22, 2025.

2. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended June 30, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on June 30, 2025.

3. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended March 31, 2025. The number of shares issued to the reporting person is based on the closing price of the common stock on March 31, 2025.

4. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended December 31, 2024. The number of shares issued to the reporting person is based on the closing price of the common stock on December 31, 2024.

5. Reflects shares of common stock issued to the reporting person under the issuer's 2024 Incentive Plan in accordance with the issuer's non-employee director compensation policy for services as a director during the quarter ended September 30, 2024. The number of shares issued to the reporting person is based on the closing price of the common stock on September 30, 2024.

	/s/ David L. Wickersham	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did VSee Health (VSEE) disclose for David L. Wickersham?

The filing reports that director David L. Wickersham acquired multiple blocks of VSee Health common stock on September 19, 2025, all coded as acquisitions of non-derivative shares.

How many VSee Health shares were in one of the reported grants to David L. Wickersham?

One reported award granted 21,870 shares of VSee Health common stock at a price of $0.69 per share, leaving him with 282,397 shares beneficially owned after that transaction.

What is the source of the shares awarded to VSee Health director David L. Wickersham?

The footnotes state that the shares were issued under VSee Health's 2024 Incentive Plan pursuant to the non-employee director compensation policy for his service as a director.

Which service periods do these VSee Health stock grants to David L. Wickersham cover?

The grants compensate Wickersham for board service in quarters ended September 30, 2025, June 30, 2025, March 31, 2025, December 31, 2024, and September 30, 2024.

How were the numbers of VSee Health shares in each grant to David L. Wickersham determined?

For each quarter, the number of shares was based on the closing price of VSee Health common stock on the specified date in the footnotes, such as September 22, 2025 and June 30, 2025.

Does the Form 4 show whether David L. Wickersham holds VSee Health shares directly or indirectly?

The transactions list the ownership form as Direct (D) with no separate nature of indirect beneficial ownership, indicating direct beneficial ownership of the reported shares.